Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 195-205

  Natarajan, Venkatachalam ^a   Krithica, Natarajan ^a   Madhan, Balaraman ^a   Sehgal, Praveen Kumar ^a  

^a CENTRAL LEATHER RESEARCH INSTITUTE   (India)

Author keywords

Controlled release; Drug delivery; Intra articular; Microspheres; Polycaprolactone; Quercetin; Rheumatoid arthritis

Indexed keywords

MICROSPHERE; POLYCAPROLACTONE; QUERCETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; RHEUMATOID ARTHRITIS; X RAY DIFFRACTION;

EID: 78650042455     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22266     Document Type: Article

References (30)

1. Jackson JK, Higo T, Hunter WL, Burt HM. 2006. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 55: 168-175.
2. Yang X, Zhu B, Dong T, Pan P, Shuai X, Inoue Y. 2008. Interactions between an anticancer drug and polymeric micelles based on biodegradable polyesters. Macromol Biosci 8: 1116-1125.
3. Guardia T, Rotelli AE, Juarez AO, Pelzer LE. 2001. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. Farmaco 56: 683-687.
4. Mamani-Matsuda M, Kauss T, Al-Kharrat A, Rambert J, Fawaz F, Thiolat D, Moynet D, Coves S, Malvy D, Mossalayi MD. 2006. Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. Biochem Pharmacol 72: 1304-1310.
5. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, Theoharides TC. 2006. Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol 148: 208-215.
6. Min YD, Choi CH, Bark H, Son HY, Park HH, Lee S, Park JW, Park EK, Shin HI, Kim SH. 2007. Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line. Inflamm Res 56: 210-215.
7. Tiku ML, Gupta S, Deshmukh DR. 1999. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radic Res 30: 395-405.
8. Gugler R, Leschik M, Dengler HJ. 1975. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9: 229-234.
9. Larsen C, Ostergaard J, Larsen SW, Jensen H, Jacobsen S, Lindegaard C, Anderson PH. 2008. Intra-articular depot formulation principles: Role in the management of postoperative pain and arthritic disorders. J Pharm Sci 97: 4622-4654.
10. Liggins RT, Cruz T, Min W, Liang L, Hunter WL, Burt HM. 2004. Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: Biocompatibility and efficacy determinations in rabbits. Inflamm Res 53: 363-372.
11. Fernandez-Carballido A, Herrero-Vanrell R, Molina-Martinez IT, Pastoriza P. 2004. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Int J Pharm 279: 33-41.
12. Liang LS, Jackson J, Min W, Risovic V, Wasan KM, Burt HM. 2004. Methotrexate loaded poly(L-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci 93: 943-956.
13. Liang LS, Wong W, Burt HM. 2005. Pharmacokinetic study of methotrexate following intra-articular injection of methotrexate loaded poly(L-lactic acid) microspheres in rabbits. J Pharm Sci 94: 1204-1215.
14. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. 2004. Celecoxib incorporated chitosan microspheres: In vitro and in vivo evaluation. J Drug Target 12: 549-557.
15. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. 2004. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. J Pharm Pharmacol 56: 1091-1099.
16. Puebla P, Pastoriza P, Barcia E, Fernandez-Carballido A. 2005. PEG-derivative effectively modifies the characteristics of indomethacin-PLGA microspheres destined to intra-articular administration. J Microencapsul 22: 793-808.
17. Aberturas MR, Molpeceres J, Guzman M, Garcia F. 2002. Development of a new cyclosporine formulation based on poly(caprolactone) microspheres. J Microencapsul 19: 61-72.
18. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. 2000. Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro/in vivo evaluation. Int J Pharm 195: 179-188.
19. Gerwin N, Hops C, Lucke A. 2006. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 58: 226-242.
20. Budavari S. 1989. The Merck index: An encyclopedia of chemicals, drugs and biologicals. 11th edition. USA: Merck & Co, Inc.
21. Hombreiro Perez M, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, Bodmeier R, Maincent P. 2000. The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J Control Release 65: 429-438.
22. Mundargi RC, Srirangarajan S, Agnihotri SA, Patil SA, Ravindra S, Setty SB, Aminabhavi TM. 2007. Development and evaluation of novel biodegradable microspheres based on poly(d, l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: In vitro and in vivo studies. J Control Release 119: 59-68.
23. Nahata T, Saini TR. 2008. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine. J Microencapsul 25: 426-433.
24. Patricia AC, Herminio CD, Maria HG. 2009. Preparation and characterization of flurbiprofen-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres. J Microencapsul 25: 170-178.
25. Dasaratha Dhanaraju M, Vema K, Jayakumar R, Vamsadhara C. 2003. Preparation and characterization of injectable microspheres of contraceptive hormones. Int J Pharm 268: 23-29.
26. Moon YJ, Wang L, Cenzo RD, Morris ME. 2008. Quercetin pharmacokinetics in humans. Biopharm Drug Dispos 29: 205-217.
27. Jeong JC, Lee J, Cho K. 2003. Effects of crystalline microstructure on drug release behavior of poly(epsilon-caprolactone) microspheres. J Control Release 92: 249-258.
28. Dhanaraju MD, Gopinath D, Ahmed MR, Jayakumar R, Vamsadhara C. 2006. Characterization of polymeric poly(epsilon-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids. J Biomed Mater Res A 76: 63-72.
29. Gibaud S, Jabir Al Awwadi N, Ducki C, Astier A. 2004. Poly(epsilon-caprolactone) and Eudragit microparticles containing fludrocortisone acetate. Int J Pharm 269: 491-508.
30. James S. 2005. Injectable dispersed systems: Formulation, processing, and performance. Florida, USA: Taylor & Francis Group, LLC.